banner

Posts tagged as: cellceutix corporation back to homepage

Sunshine Biopharma Shares Jump on Multi-Drug Resistant Breast Cancer Presentation News Sunshine Biopharma Shares Jump on Multi-Drug Resistant Breast Cancer Presentation News(0)

With the backdrop of news on Monday that Sunshine Biopharma, Inc. (OTCBB:SBFM) will be presenting new scientific data at the American Association for Cancer Research Meeting in Chicago, IL (to be held on March 31 – April 4, 2012), shares of the junior biotech surged a cool 100% to close Monday’s trading at 50 cents each. Read More

Cellceutix Featured on Front Page of Boston Business Journal Cellceutix Featured on Front Page of Boston Business Journal(0)

Cellceutix Corporation (OTCBB: CTIX) (“the Company”), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat unmet medical conditions, is pleased to announce that it was featured Friday, January 20th on the front page of the Boston Business Journal print edition. Owned by American City Business Journals, the Boston Business Journal is available in both print and online versions and reaches hundreds of thousands of subscribers each month. Read More

Cellceutix Plans Clinical Trials for Psoriasis and Cancer Drugs in 2012 Cellceutix Plans Clinical Trials for Psoriasis and Cancer Drugs in 2012(0)

Cellceutix Corporation (OTCBB: CTIX) (“the Company”), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat unmet medical conditions, is pleased to provide corporate updates on Kevetrin™, its novel drug in development for drug-resistant cancers, and KM-133, its compound being developed as a revolutionary psoriasis indication. Read More

BioTuesdays Says Cellceutix Better than Competition BioTuesdays Says Cellceutix Better than Competition(0)

Popular biotechnology website BioTuesdays.com published an article this morning on Cellceutix Corporation (OTCBB: CTIX) discussing the recent developments and significant potential of Cellceutix as a result of its cancer drug, Kevetrin, and other drugs in its pipeline.  The article, titled “Cellceutix’s potential breakthrough in cancer research,” spends time noting the “Holy Grail” p53 connection Read More

Cellceutix Files IND; Cancer Trials to be Held at Dana-Farber Cellceutix Files IND; Cancer Trials to be Held at Dana-Farber(0)

Cellceutix Corporation (OTCBB:CTIX) has filed its Investigational New Drug (IND) application for Kevetrin™, a novel anti-cancer drug, with the U.S. Food and Drug Administration (FDA). The Company must now wait 30 calendar days before initiating Read More

Cellceutix Confident as Cancer Compound Shows Activity in All Cancers Tested Cellceutix Confident as Cancer Compound Shows Activity in All Cancers Tested(0)

Cellceutix Updates Shareholders; Answers Questions About Clinical Trials for Novel Cancer Drug
Cellceutix Corporation (OTCQB: CTIX) (“the Company”), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat unmet medical conditions, is pleased to provide shareholders with the following update. The Company’s accomplishments in cancer have garnered much attention Read More

Cellceutix’s Kevetrin Effective Against Prostate Cancer Cellceutix’s Kevetrin Effective Against Prostate Cancer(0)

Human xenograft mouse models have shown Kevetrin, the Cellceutix Corporation (OTCQB:CTIX) drug in development as a new cancer therapy, to slow tumor growth and reduce tumor volume as released by Cellceutix today. The news release also addresses updates to the Investigational New Drug application to include the prostate cancer research and clinical protocol from the hosting hospital. To learn more, read the Cellceutix press release and get a CTIX stock quote.

Cellceutix Pens Agreement with Dana-Farber for Cancer Drug Research Cellceutix Pens Agreement with Dana-Farber for Cancer Drug Research(0)

Cellceutix Corporation (OTCQB:CTIX) announced this morning that they have signed a Laboratory Services Research Support Agreement with Dana Farber/Partners CancerCare, Inc. The agreement outlines the collaborative and laboratory support for the planned clinical trials for Kevetrin™, Cellceutix’s novel compound as an indication for cancer. Read More

Cancer News:  CEO Explains Why Cellceutix’s Leading Drug Candidate May Be a Major Breakthrough in Cancer Research Cancer News: CEO Explains Why Cellceutix’s Leading Drug Candidate May Be a Major Breakthrough in Cancer Research(0)

The CEO of Cellceutix Corporation (OTCQB: CTIX), a preclinical cancer, anti-inflammatory and autism drug developer says his company’s leading drug candidate, Kevetrin, is a new class of chemistry in medicine which has proven to this point to restore p53 (also known as the “Guardian Angel” gene ) back to a normal status so it can do its job as master regulator and see to it that the cancer cells are destroyed without damaging any DNA. Read More

OTCBB News:  Cellceutix Receives Approval for Clinical Trials from Major Cancer Center OTCBB News: Cellceutix Receives Approval for Clinical Trials from Major Cancer Center(0)

Cellceutix Corporation (OTCQB:CTIX) issued big news this morning that they have received the “thumbs-up” from one of the world’s leading cancer research centers to host the Company’s clinical trials for Kevetrin™.  Cellceutix is developing (and posting strong pre-clinical results) Kevetrin™ as an indication for a multitude of cancers including drug-resistant, pancreatic, lung, leukemia and breast cancers.  The cancer center was not disclosed, but there are several industry-leading centers in the east/northeast United States.  U.S. News recently released their list of the top cancer hospitals in the U.S.  The Top 5 included Memorial Sloan-Kettering in New York, NY; Johns Hopkins in Baltimore, MD; and Dana-Farber/Brigham and Women’s in Boston, which will have investors wondering which center will be hosting the trials Read More


Stay Informed

Receive the OTCS Newsletter *




*

* required

Dana-Farber to Host Cellceutix Trials

Cellceutix Corporation (CTIX)
Cellceutix Corporation has filed its Investigational New Drug application with the FDA. Dana-Farber and Beth Israel Deaconess Medical Center will be hosting the clinical trials for Kevetrin, Cellceutix's novel cancer drug. Read more news and get a stock quote.

Diabetes Rate Growing Exponentially

According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.

Contacts and information

Have an opinion or news that you want to share?

Social networks

Most popular categories

Disclaimer/Disclosure
© 2011 Viper Enterprises, LLC. All rights reserved.